Concise Prescribing Info
Treatment of HTN & heart failure. Post MI, hypertensive adult patients w/ impaired glucose tolerance at CV risk.
Dosage/Direction for Use
Adult HTN Initially 80 mg or 160 once daily, in patients whose blood pressure is not adequately controlled may be increased to 320 mg, or may add diuretic. Max: 320 mg once daily. Heart failure 40 mg bid. Up-titration to 80 mg to 160 mg bid should be done to the highest dose tolerated by patient. Consideration to reduce dose of concomitant diuretics. Max: 320 mg divided doses. Post MI may initiate as early as 12 hr after MI. Initial dose 20 mg bid. Therapy should be titrated to 40 mg, 80 mg & 160 mg bid over the next few wk. Starting dose 40 mg divisible tablet. Target Max: 160 mg bid. 2 wk after treatment initiation 80 mg bid. Max: 160 mg bid. Hypertensive adult patient w/ impaired glucose tolerance at CV risk 80 or 160 mg once daily. Starting 80 mg, up titration to 160 mg once daily as tolerated by patient. Childn & adolescent 6-18 yr Initial dose 40 mg once daily for <35 kg of wt, & 80 mg once daily for ≥35 kg.
Should be taken with food. Take w/ water.
Hypersensitivity. Pregnancy. Concomitant use of angiotensin receptor antagonist, valsartan or ACE inhibitors w/ aliskiren w/ type 2 diabetes.
Special Precautions
Hypotension may occur in salt &/or vol depleted patients. Patients w/ renal artery stenosis. Patients w/ hepatic impairment. Patients w/ heart failure/ post MI. Angioedema. Childn.
Adverse Reactions
HTN, abdominal pain, fatigue. Heart failure &/or post MI, dizziness, postural dizziness, hypotension, orthostatic hypotension, renal failure & impairment, hyperkalemia, syncope, headache, vertigo, cardiac failure, cough, nausea, diarrhea, angioedema, acute renal failure, elevation of serum creatinine, asthenia, fatigue.
Drug Interactions
Concomitant use of angiotensin receptor blockers including valsartan may lead to increase incidence of hypotension, hyperkalemia & changes in renal function; w/ aliskiren it should be avoided w/ type 2 diabetes. Concomitant use of K-sparing diuretics may lead to increase serum potassium & in heart failure increase serum creatinine. Concomitant use w/ NSAIDS simultaneously w/ angiotensin receptor blockers may lead to antihypertensive effect & increase risk of worsening renal function. Increase serum lithium conc & toxicity w/ concomitant use w/ ACE inhibitors or angiotensin II receptor antagonists including valsartan. Increase systemic exposure q/ rifampicin, ciclosporin or ritonavir. Increase serum potassium w/ valsartan & other substance that inhibit renin angiotensin aldosterone system.
MIMS Class
Angiotensin II Antagonists
ATC Classification
C09CA03 - valsartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.
Torval-160 FC tab 160 mg
30's (P1,290/box)
Torval-80 FC tab 80 mg
30's (P804/box)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in